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AbstrAct
Introduction Parkinson’s disease (PD) with mild cognitive 
impairment (MCI-PD) or dementia (PDD) and dementia 
with Lewy bodies (DLB) are characterised by motor and 
‘non-motor’ symptoms which impact on quality of life. 
Treatment options are generally limited to pharmacological 
approaches. We developed a psychosocial intervention to 
improve cognition, quality of life and companion burden 
for people with MCI-PD, PDD or DLB. Here, we describe 
the protocol for a single-blind randomised controlled trial 
to assess feasibility, acceptability and tolerability of the 
intervention and to evaluate treatment implementation. 
The interaction among the intervention and selected 
outcome measures and the efficacy of this intervention in 
improving cognition for people with MCI-PD, PDD or DLB 
will also be explored.
Methods and analysis Dyads will be randomised into 
two treatment arms to receive either ‘treatment as usual’ 
(TAU) or cognitive stimulation therapy specifically adapted 
for Parkinson’s-related dementias (CST-PD), involving 
30 min sessions delivered at home by the study companion 
three times per week over 10 weeks. A mixed-methods 
approach will be used to collect data on the operational 
aspects of the trial and treatment implementation. 
This will involve diary keeping, telephone follow-ups, 
dyad checklists and researcher ratings. Analysis will 
include descriptive statistics summarising recruitment, 
acceptability and tolerance of the intervention, and 
treatment implementation. To pilot an outcome measure 
of efficacy, we will undertake an inferential analysis to test 
our hypothesis that compared with TAU, CST-PD improves 
cognition. Qualitative approaches using thematic analysis 
will also be applied. Our findings will inform a larger 
definitive trial.
Ethics and dissemination Ethical opinion was granted 
(REC reference: 15/YH/0531). Findings will be published 
in peer-reviewed journals and at conferences. We will 
prepare reports for dissemination by organisations 
involved with PD and dementia.
trial registration number ISRCTN (ISRCTN11455062).
IntroductIon
Background and rationale
Within the spectrum of Lewy body disor-
ders, cognitive impairment can manifest as 
Parkinson’s disease (PD) dementia (PDD), 
Parkinson’s disease with mild cognitive 
impairment (MCI-PD) and dementia with 
Lewy bodies (DLB). Only very limited drug-
based treatments are available for PDD, 
and no medications have been licensed for 
MCI-PD and DLB. Without adequate manage-
ment of the non-motor aspects of these 
conditions, the risk of being admitted to care 
is very high. Increasing the availability and the 
evidence base for non-drug-based therapies 
for dementia and mild cognitive impairment, 
such as psychosocial interventions, is a key 
objective of England’s National Dementia 
Strategy1 and other national dementia policy 
drivers. Unfortunately, there is almost no 
evidence to support their use in people with 
more complex forms of dementia, such as 
dementias associated with Parkinson’s-related 
disorders.2 Thus, there is a need to extend 
psychosocial therapies to this population. 
Unpublished data provided by public and 
patient involvement (PPI) representatives 
and Parkinson’s expert consultees involved in 
this project support this view.
For people with dementia unrelated to 
Parkinson’s-related disorders, psychosocial 
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Protocol
strengths and limitations of this study
 ► The use of psychosocial therapies for cognitive 
impairment in movement disorders is important and 
under-researched.
 ► This study uses a range of process and exploratory 
measures to ascertain the feasibility of undertaking 
a large efficacy randomised controlled trial powered 
to assess a range of complex outcomes in both 
affected participants and their companions.
 ► The efficacy of the intervention in improving 
cognition will be evaluated.
 ► Dyads will be recruited from multiple clinical sites to 
reduce potential bias when recruiting from a single 
site.
 ► Recruiting to target will be a challenge, due to the 
complexity of the intervention, the relative frailty of 
some participants and the existing responsibilities 
of the companion.
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therapies, such as reality orientation or reminiscence 
therapy, have been in use for some time.3 Recently, in the 
UK, several large-scale multicentred trials of psychosocial 
interventions for dementia have been conducted, for 
example, goal-oriented cognitive rehabilitation4 and indi-
vidual cognitive stimulation therapy (iCST)5; however, 
these have either specifically excluded people with PD/
DLB or not been tailored to meet their needs. One of the 
most widely accepted psychosocial therapies for dementia, 
which has been accepted for use in the National Health 
Service (NHS) and is part of the National Institute for 
Health and Care Excellence6 guidelines for dementia 
care is structured group cognitive stimulation therapy 
(CST).7 Based on these recommendations, as well as its 
relatively widespread use and availability, CST was chosen 
by the research team as a candidate therapy to adapt for 
individuals with Parkinson’s-related dementias.
CST was originally developed from a Cochrane system-
atic review of psychological interventions for people with 
dementia8 and has been shown to be cost-effective, to 
improve quality of life and to enhance cognition to an 
extent comparable with trials of cholinesterase inhibi-
tors.5–7 CST is based on the principle that stimulating 
engagement in cognitive and social activity enhances 
cognitive function and quality of life. However, in spite 
of the success of the therapy in a group setting, it was 
recognised that not all people with dementia may have 
access to, or wish to participate in, group activities. CST 
was therefore adapted for home-based individualised 
administration (via a study companion) in the form of 
‘individual CST’ (iCST).5
The efficacy of iCST was recently investigated in a 
26-week multicentre, single-blind, randomised controlled 
trial (RCT).5 The findings revealed a significant improve-
ment in the quality of the relationship of the person 
with dementia and their study companion, as well as an 
improvement in health-related quality of life for compan-
ions (designated ‘caregivers’). Furthermore, iCST was 
found to be feasible for people who found travel a barrier 
to participation. Outcomes related to those who support 
or care are particularly important, since the perceived 
burden of care has been shown to be significantly related 
to the extent of associated cognitive impairment in the 
person living with Parkinson’s-related dementia.9 This may 
be in part due to the added responsibility of managing the 
impact of concurrent cognitive, psychiatric and physical 
impairments in the cognitively impaired person. None-
theless, in spite of the positive findings mentioned above, 
iCST did not appear to improve cognition or quality of 
life of the cognitively impaired participants themselves.
While CST as a psychosocial intervention for people 
with Parkinson’s-related dementia has potential, early 
consultation with PPI and Parkinson’s expert groups 
suggested the need for adaptation. Thus, the first step 
was to undertake a ‘therapy adaptation’ process in order 
to meet the specific needs of people with PDD, MCI-PD 
or DLB. This will be described in detail in a subsequent 
paper. The adaptation was deemed necessary due to the 
added complexity of the symptoms related to PD which 
may include frequent episodes of confusion, marked 
hallucinations and delusions, high rates of apathy, a 
myriad of motor symptoms and dependency on compan-
ions due to physical disability. It was hypothesised that 
cognitive stimulation therapy specifically adapted for 
Parkinson’s-related dementias (CST-PD) may improve 
cognitive function and quality of life in this popula-
tion and could potentially have a positive effect on 
companions and other outcomes.
The protocol outlined here describes a feasibility 
and exploratory study embedded within a pilot trial of 
CST-PD, which will be delivered by companions. This 
study will address some of the iterative steps in the process 
involved in developing a complex intervention for people 
with dementia, as outlined by the UK’s Medical Research 
Council (MRC) guidance on the topic.10 First, it is a 
test to explore whether it is possible to implement and 
evaluate this particular complex intervention, including 
aspects of treatment implementation and dosing, and 
second, it will be a small-scale trial of the intervention to 
estimate the treatment effect and its variance on a single 
main outcome as well as exploratory subsidiary outcomes.
overall aim
The purpose of this work is to gather the infor-
mation needed to design a subsequent full-scale, 
definitive RCT powered to evaluate the efficacy of CST-PD 
in improving a range of outcomes relevant to people with 
PDD, MCI-PD or DLB and their companions.
objectives
To fulfil our aim, we will achieve the following objectives:
Primary objectives
 ► An evaluation of the operational aspects of the study 
including recruitment, acceptance of the intervention 
and assessments, and loss to follow-up;
 ► A process evaluation of the intervention including 
whether the intervention can be delivered, received 
and enacted as intended,11 as well as acceptability 
and tolerability of the intervention by the dyads 
(people with MCI-PD, PDD or DLB, referred to as 
participants, and their study partners, referred to as 
companions).
Secondary objectives
 ► An exploration of the potential efficacy of the 
intervention on a single primary outcome, cognition;
 ► An exploration of the potential possible outcome 
measures in terms of feasibility, clinically meaningful 
change and relationship to the intervention.
Research questions and hypotheses
The following are research questions for the feasibility 
and exploratory study:
 ► Is it possible to recruit sufficient dyads in a timely 
manner?
 ► What is the acceptability and tolerability of the 
intervention by dyads?
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 ► Which are the most clinically meaningful and 
acceptable outcomes by which to assess efficacy?
 ► Based on the findings, what would the sample size of 
a fully powered definitive RCT of the intervention be?
The following is the hypothesis to explore potential effi-
cacy of the intervention:
 ► In people with PDD, MCI-PD or DLB, the change in 
cognitive function from baseline to withdrawal of CST-
PD at 12 weeks will favour the intervention compared 
with treatment as usual (TAU).
MeThods
This protocol was prepared in accordance with SPIRIT 
2013 statement12 (checklist is available as an online 
supplementary file). The trial is registered with the 
ISRCNT (ISRCTN11455062); all study-related items 
from the WHO Trial Registration Data Set are avail-
able at the registry. The protocol lies within a research 
programme comprising a series of sequential steps in the 
development, feasibility testing, piloting and eventual 
full-scale trialling of a complex psychosocial intervention 
for people with PDD, MCI-PD or DLB. The programme 
has followed the UK’s MRC’s updated Guidance on 
‘Developing and Evaluating Complex Interventions10 
and is now at the feasibility, exploratory and pilot trial 
stage, which we describe here. Specifically, this part of 
the programme is a fully controlled randomised single-
blind exploratory pilot trial with an embedded feasibility 
process evaluation and evaluation of new outcomes. The 
protocol for the process evaluation is not reported here 
but will form the basis of other papers. The pilot trial is 
designed and powered to test the hypothesis that CST-PD 
is superior to TAU for people with PDD, MCI-PD or DLB 
in improving cognitive function when assessed at baseline 
and 12 weeks post-randomisation. The therapy will be 
delivered in participants’ homes with recruiting sites in 
locations in Greater Manchester and other regions in the 
UK. A CONSORT-style flow chart for the trial is shown in 
figure 1.
The feasibility study is designed to (1) ascertain the 
feasibility of conducting the trial in a small scale and (2) 
explore secondary outcomes for which the trial is not 
powered to detect efficacy. It is vital to address these issues, 
since in the case of an intervention such as CST-PD, there 
are multiple components working in synergy to produce 
change, and it is not clear at the outset which compo-
nents may result in change and at which level this may 
occur (eg, individual, companion, relationship and so 
on).10 Thus, the ‘dimensions of complexity’ highlighted 
in the MRC’s new guidance for developing and evaluating 
complex interventions10 that need to be considered and 
accounted for in the trial design are outlined in table 1. A 
single team will evaluate the three sets of outcomes (effi-
cacy trial, feasibility study and exploratory study) in order 
to foster an ongoing process of integration of evidence as 
to the conduct of the different steps in the study and trial, 
as suggested by Moore et al.13
dyad selection
 Sixty-four dyads will be asked to participate. Inclusion 
and exclusion criteria are listed in table 2.
We will recruit from centres based at Manchester, 
Warrington, North East London, and Derby, in the UK. 
Centres will have established memory or movement 
disorder clinics and high volumes of people with PDD, 
MCI-PD or DLB. As recruitment may be influenced 
by clinic closures during certain times of the year (eg, 
Christmas and the summer months), recruitment will 
be carried out over 15 months to obtain an accurate 
estimate of recruitment rate. The study will be adver-
tised on UK-based charity websites (eg, Parkinson’s UK, 
the Lewy Body Society) and through Join Dementia 
Research (https://www. joindementiaresearch. nihr. ac. 
uk). User-friendly information brochures (available as on 
online supplementary file) will be available at memory 
and movement disorder clinics and support groups, and 
information talks will be given at Parkinson’s UK commu-
nity groups. In a recent trial of iCST involving people with 
non-PD dementias and their companions, the recruit-
ment target (356 dyads over 15 months) was achieved5; 
however, the level of companion burden experienced in 
the non-PD dementia population may be less compared 
with that experienced by companions of people with 
PDD, MCI-PD and DLB, and this may influence recruit-
ment.14 Furthermore, Parkinson’s-related dementia is 
much less common compared with dementia of the 
Alzheimer type.15 Therefore, one of the goals of this study 
is to obtain an accurate estimate of the recruitment rate 
for participants and their companions.
sample size
A predetermined sample size for the feasibility aspects of 
this study is not required, since inferential statistics will 
only be exploratory. The sample size is determined by 
that required to detect a clinical meaningful difference 
in our primary outcome measure, cognitive function. 
To determine sample size, we referred to the previous 
literature7 8 16 and, taking a conservative approach, have 
estimated the standardised effect size on cognition of 
the parent form of the intervention to be 0.4. Thus, 
assuming 80% power and a correlation coefficient of 0.5 
between baseline and endpoint on cognitive outcomes, 
the required sample size is 27 completers per group. 
By enrolling 32 dyads per group, it will allow for a 15% 
attrition rate (consistent with pilot sample guidance17). 
For the secondary, exploratory outcomes, the proposed 
sample size of 27 per group is within the recommended 
guidelines (24–50 participants18 19) required to estimate 
the standard deviation (SD) for a sample size calculation.
randomisation and blinding
Eligible dyads will be identified at recruiting centres by 
trial collaborators (principal investigators) and research 
nurses and therapists. Participant and companion infor-
mation sheets outlining the study objectives, risks and 
benefits will be shared with each dyad. Informed consent 
from the participant and companion, based on the Good 
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Figure 1 CONSORT-style flow chart.
Clinical Practices guidelines published by International 
Council for Harmonisation,20 will be gained during the 
home screening visit (participant and companion infor-
mation sheets and informed consent forms are available 
as on online supplementary file). In line with the afore-
mentioned iCST/CST trials, guidance from the British 
Psychological Society on evaluation of capacity will be 
followed. In the event of a participant with PDD/DLB 
not having capacity at study entry or losing capacity 
after study entry, the ethics committee has approved 
the INVEST trial implementer to gain consent from an 
acceptable, nominated representative. During the home 
screening, the unblinded trial implementer will admin-
ister the Montreal Cognitive Assessment (MoCA)21 and 
Schwab and England Activities of Daily Living Scale22 to 
confirm eligibility and collect demographic data. Once 
the participant and companion are consented, blinded 
assessors will conduct baseline assessments in the dyad’s 
home.
Following baseline assessment, the unblinded trial imple-
menter will randomise the dyad to one of two arms: CST-PD 
or TAU. A tamper proof process of single-strata, blocked 
randomisation will be applied and communicated via tele-
phone and confirmatory email by an independent arbiter, 
the Manchester Academic Health Science Centre Clinical 
Trials Unit. Due to the nature of the intervention, dyads will 
not be blind to treatment allocation.
Immediately following the intervention period (see 
below for details), the blinded assessors will visit dyads in 
their home to conduct post-test assessments. The unblind 
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Table 1 Description of ‘dimensions of complexity’ in the adapted study as per MRC’s guidelines10
Dimension Reason for complexity
Number of and interactions between components 
within the experimental interventions
Since the intervention will be delivered by the companion and we 
anticipate that no two companions or participants will have the same 
skills, interests or deficits, there may be a degree of variation in each 
therapy session. The therapy is based on this assumption and is 
designed to maximise outcomes by adopting a person-centred approach. 
Participants choose the activities they are most interested in from a library 
of over 60 cognitively stimulating topics. Companions subsequently 
personalise the activity through verbal, visual, tactile, auditory, gustatory or 
olfactory cues. Thus, the therapy subscribes to a structured, yet tailored, 
approach, delivering an intervention that is standardised with respect to 
dose and delivery but variable with respect to content.
Number and difficulty of behaviours required by 
those delivering or receiving the intervention
Standardised companion training is critical to minimise heterogeneity. 
All companions will be trained to criterion and their skills monitored over 
time. This element of treatment fidelity will reduce the likelihood of non-
significant results at the end of the study being attributed to poor training 
rather than an ineffective intervention. Companions will receive a minimum 
of 2 hours training and must have sufficient cognitive function (by not 
meeting clinical criteria for dementia) to be able to deliver the therapy. 
Companions’ ability to deliver the therapy will be self-assessed and 
researcher rated at the end of the training and monitored throughout the 
study.
Number and variability of outcomes Although the trial is powered to assess cognitive functioning as the main 
outcome, it is likely that there may be effects on different outcomes 
such as behaviour, companion variables, relationship features and health 
economic issues.
A good theoretical understanding is needed of 
how the intervention causes change, so that weak 
links in the causal chain can be identified and 
strengthened
The background literature of evidence of potential mechanisms, as well as 
clinical experience, has suggested that each function of the intervention 
can be linked to identifiable intermediate impacts and final outcomes and 
can be outlined in a logic model32 33 which will be outlined elsewhere.
MRC, Medical Research Council.
Table 2 Inclusion and exclusion criteria for participants and companions
Inclusion criteria—participant Exclusion criteria—participant
Have a diagnosis of possible or probable PDD, MCI-PD 
or DLB. Diagnosis will be based on standard clinical 
diagnostic criteria34–36 determined by the referring 
clinician and verified on screening.
Lack sufficient physical and mental capability to participate in the 
therapy. Capability will be based on clinical impression at the initial 
screening visit and informed by scores obtained on the Schwab and 
England Activities of Daily Living Scale22 and MoCA.21
Be willing to participate in 30 min sessions of the 
intervention, three times per week.
Current involvement in any other dementia intervention research 
study.
Be on a stable on medication regimen for at least 
4 weeks, prior to study entry.
Unable to understand conversational English, are non-literate or 
have physical or mental illness severe enough to preclude 
participation in the study.
Living in residential care.
Inclusion criteria—companion Exclusion criteria—companion
Provide care or support for a person with Parkinson’s-
related dementia.
Lack capacity to consent to the study to ensure and able to 
undertake the training and delivery of the intervention.
Be willing and well enough to deliver 30 min sessions of 
the intervention, three times per week.
Unable to understand conversational English, are non-literate or 
have physical or mental illness severe enough to preclude 
participation in the study.
Be familiar with the participant’s physical and mental 
health and able to provide feedback about this to the 
study team.
A diagnosis of dementia; the presence of dementia in the 
companion will be determined by self-report as well as clinical 
impression informed by performance on the MoCA.21
DLB, dementia with Lewy bodies; MoCA, Montreal Cognitive Assessment; MCI-PD, Parkinson’s disease with mild cognitive impairment; PDD, 
Parkinson’s disease dementia.
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Table 3 Themes and sample topics from the CST-PD 
manual
Session theme Sample topics
Personal life Childhood, family, relationships
Food World cuisine, staying healthy, 
ingredients
Hobbies and leisure My perfect day, pets, gardening
Art History of art, Lowry and Turner, 
architecture
Media and 
entertainment
Musical instruments, current affairs, 
technology
Nature Weather, water, animal kingdom
Seasons Spring, Summer, Autumn, Winter
Travel and culture Continents, flags, Blackpool
Games and tasks Board game, proverbs, colouring and 
doodling
trial implementer will remind all dyads to maintain the 
blind during the assessment. Following assessment, 
blinded assessors will be asked to record the arm to which 
they believed the dyad was allocated to.
Active intervention
The active intervention, CST-PD, is based on conventional 
CST7 and iCST5 and was developed by means of an iter-
ative process involving significant user, companion and 
professional input. This adaptation process is described 
in detail elsewhere and has resulted in a condition-spe-
cific cognitive stimulation therapy manual with training 
guidance. The manual comprises over 60 topics catego-
rised into nine different themes (table 3). Each topic 
contains several cognitively stimulating activities, for 
example, discussion suggestions, word association and 
creative tasks. Activities vary in complexity and can be 
matched and adapted to suit the needs of the participant. 
It is recommended that the companion-guided therapy is 
delivered in 30 min sessions, three times a week over 10 
weeks.
A specially trained trial implementer (eg, nurse, ther-
apist or researcher) will visit the dyad at home and 
provide therapy training to the companion. During the 
training session, the companion will receive the therapy 
manual, an activity resources pack, the therapy log 
(companion’s diary), information related to the history 
and objectives of the therapy, and guidance on the nine 
core principles of the therapy. The trial implementer will 
guide the participant through a sample session, and the 
companion will be encouraged to continue with a short 
session afterwards. The trial implementer will provide 
constructive feedback to the companion after the session. 
Once the 10-week intervention period has started, the 
trial implementer will contact the companion weekly to 
confirm ongoing consent and adherence and to provide 
therapy support (if needed). In exceptional circum-
stances and where telephone assistance is not sufficient 
(eg, companion doubting confidence in their ability to 
continue delivering the training), further home visits 
may be made for ‘refresher’ training sessions. If the dyad 
is unable to complete any therapy for more than three 
successive weeks, they will be withdrawn from the trial. To 
standardise training, the trial implementer will follow a 
detailed training protocol.
‘treatment as usual’ (control) group
For the purposes of the feasibility evaluation, the inclusion 
of a control group (ie, TAU) is important because it allows 
for a more realistic evaluation of the operational aspects 
(ie, recruitment, retention and randomisation) as well as 
the implementation of the intervention.23 If conducted 
in an unblinded, non-randomised manner, the outcomes, 
particularly for a complex psychosocial intervention such 
as is being tested here, may be quite different. Further-
more, since previous evidence enabled us to power the 
primary outcome measure, cognitive function, for an 
evaluation of efficacy, a pilot trial was considered possible 
and this required inclusion of a control group to account 
for the natural progression of symptoms during the trial. 
Specifically, in the TAU comparator arm, dyads will not 
receive any additional intervention to their standard NHS 
treatment for PD and cognitive impairment or DLB. Typi-
cally, this involves dopamine replacement therapy for the 
symptomatic relief of Parkinsonism, cognitive enhancing 
medication (eg, cholinesterase inhibitors) and support 
from a Parkinson’s disease nurse specialist. Since people 
with Parkinson’s-related dementia tend to have signif-
icant symptoms in multiple domains, the support of 
occupational therapist, speech and language therapists 
and physiotherapists is often required. These interven-
tions will be available to both the TAU as well as those 
dyads randomised to the active treatment arm. Treatment 
fidelity will be actively monitored in the control group, as 
it is in the experimental group, to ensure that the control 
group do not receive an active intervention component 
which could reduce the effect size between the experi-
mental and control groups or, similarly, to ensure that an 
iatrogenic component is not added to the control group 
which could artificially inflate the difference in outcomes 
between the two groups.24
Patient and public involvement
Service users, service providers and PPI representatives 
have been involved in the developmental stages leading 
up to this study. To ensure that PPI continues to be inte-
grated throughout the INVEST trial, two couples (both 
involving a person living with PD and their life partner) 
are active members of the Trial Steering Group (TSG). 
Additional PPI representatives will be involved in the 
piloting of interview schedules, advising on the language 
used to raise awareness of the study, promoting the study 
through networks and disseminating the research.
outcome measures
Feasibility and acceptability measures
We shall describe individual demographic and clinical 
characteristics of participants and companions. We will 
evaluate several feasibility and acceptability components 
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Table 4 Description of feasibility measures
Feasibility component Measure Described as
Recruitment Recruitment rate The number of dyads consented/number eligible
Attrition Attrition rate The number of dyads withdrawn/number consented
Therapy adherence Therapy log 
(companion’s diary)
The total dose (frequency and duration) of the intervention delivered, 
recorded by the companion after each session
Acceptability of therapy Therapy log 
(companion’s diary)
Companions will rate the extent to which (in each session) the participant 
was interested, motivated, gained a sense of achievement; took the initiative 
and displayed emotional responses. Ratings will be made on a 5-point Likert 
scale on which ‘1’= strongly disagree and ‘5’=strongly agree.
Acceptability of 
assessments
Interview record form/
focus group
Mixed methods. Quantitative data will include response rates, time taken 
and level of missing data. Qualitative investigation (assessors interview 
record form/focus group with blinded assessor) will explore the process: 
how were the assessments administered, queries raised by respondents, 
respondents’ markings on the instrument, practical difficulties observed and 
strategies employed to overcome challenges.
with a series of outcome measures outlined in table 4. 
The recruitment and attrition rates to inform subsequent 
trials will be estimated.
To triangulate the data, qualitative semistructured 
interviews will be conducted with a small sample following 
completion of the intervention. The interviews will seek 
to ascertain acceptability information relating to expec-
tations and experiences of the therapy and barriers 
and facilitators to completing the therapy. Data will be 
collected from a purposive sample of 12 dyads, since new 
themes are reported to occur infrequently beyond this 
sample size.25 The purposive subsample will aim to maxi-
mise diversity in dyads’ characteristics to increase the 
validity and transferability of research findings to other 
settings. The sample will include (1) people taking part 
in the therapy, (2) men and women, (3) people of ages 
crossing the age range of the main sample and (4) people 
with different levels of cognitive ability (eg, PDD and 
MCI-PD). Approximately three to four dyads will be 
invited for interview from each centre.
All audio-recorded interview data will be transcribed 
verbatim and analysed using thematic analysis or other 
appropriate analytical processes.
Primary and exploratory outcome measures
The piloted efficacy and exploratory outcome measures 
for the participant are outlined in table 5a and the 
exploratory outcome measures for the companion in 
table 5b. The pilot efficacy measure on which the study 
has been powered is cognitive function as assessed using 
the Addenbrooke’s Cognitive Examination III26 and the 
Everyday Cognition Questionnaire.27 Although the pilot 
trial has been powered on a previously reported effect 
size, the adaptation of the therapy and single outcome 
measure means that any potential treatment effects will be 
interpreted cautiously in order to not mislead the subse-
quent sample size and power calculation of the full RCT 
with multiple outcomes.28 With this caveat, we will test 
the hypothesis that compared with the TAU group, the 
difference in the total cognitive score between baseline 
and endpoint will be significantly greater in the experi-
mental group. We will undertake a complete case analysis, 
only including trial completers without missing data, as 
well as an additional analysis based on last observation 
carried forward for dyads with missing data. Group differ-
ences in the change of outcome measures will be assessed 
using t-test or analysis of covariance adjusting for baseline 
differences, including cognitive stage at baseline.
Ascertaining efficacy of a complex intervention can be 
challenging since anticipating which outcome measures 
might be affected by the intervention as either a final or 
intermediate outcome (eg, mediators or moderators)29 
can be difficult. Thus, we have carefully considered the 
underlying theoretical frameworks driving the process 
and consequently have incorporated several exploratory 
outcome variables to assist in determining what a clini-
cally meaningful difference in the outcome might be 
(table 4). Data on exploratory outcome measures will 
be presented and summarised using means and SDs or 
alternatives in the case of non-normally distributed data. 
Data will be compared with previous trials of CST and 
iCST to understand the possible impact of the adapted 
therapy. This information can then be used to inform a 
subsequent full-scale hypothesis testing study designed to 
detect the smallest clinically meaningful difference.23
cost-effective analysis
To obtain data on the potential health economic and 
cost-effectiveness implications of the intervention in a 
subsequent fully powered RCT, we will assess the use of 
the Client Services Receipt Inventory30 and the EuroQoL 
5D31 by using baseline and follow-up data to estimate the 
validity and responsiveness of these questionnaires.
Adverse events
CST is not known to be associated with adverse events; 
however, we will monitor for such events. In the unlikely 
event that an adverse event occurs, the dyad will be 
directed to relevant health services, and the event will be 
recorded on a structured form. Advice on how to proceed 
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Table 5 Primary and exploratory outcome measures
Measure/author Purpose Time point
a) Efficacy and exploratory outcome measures for the participant
  The Addenbrooke’s Cognitive 
Examination III26
Assesses cognitive function Baseline/post-test
  Everyday Cognition Questionnaire27 Measures everyday cognition in people with movement 
disorders
Baseline/post-test
  Pill Questionnaire37 Measures functional capacity Baseline/post-test
  Lille Apathy Rating Scale38 A scale to detect and quantify apathy Baseline/post-test
  Relationship Satisfaction Scale39 Assesses level of satisfaction in a relationship Baseline/post-test
  The Brief Resilience Scale40 Assesses the ability to recover from stress Baseline/post-test
  Interpersonal Reactivity Index41 Measures empathetic concern Baseline/post-test
  Hospital Anxiety and Depression Scale42 Assesses depression and anxiety Baseline/post-test
  Parkinson’s Disease Questionnaire-3943 A Parkinson’s disease-specific quality of life measure Baseline/post-test
  Dementia Cognitive Fluctuation Scale44 Assesses proxy-reported fluctuations in cognition Baseline/post-test
  The Neuropsychiatric Inventory45 Assesses presence or absence of behavioural disturbances Baseline/post-test
  EuroQoL 5D31 Used for calculation of quality-adjusted life-years Baseline/post-test
  Client Services Receipt Inventory30 Collects information about medications and services used 
before entering the trial and during the trial
Baseline/post-test
b) Exploratory outcome measures for the companion
  Short Form-12 Health Survey46 Measures an individual’s perception of their physical and 
mental health
Baseline/post-test
  Relationship Satisfaction Scale39 Assesses level of satisfaction in a relationship Baseline/post-test
  Brief Resilience Scale40 Assesses the ability to recover from stress Baseline/post-test
  Hospital Anxiety and Depression Scale42 Assesses depression and anxiety Baseline/post-test
  Zarit Burden Interview47 Measures companion burden due to caregiving Baseline/post-test
  Dyadic Relationship Scale48 Measures positive and negative aspects of the dyadic 
relationship
Baseline/post-test
  Relatives’ Stress Scale49 Measures perceived stress associated with caregiving Baseline/post-test
  Family caregiving role50 Measures aspects of caregiving related to satisfaction, love 
and anger
Baseline/post-test
(ie, to withdraw the dyad temporarily or permanently) 
with be sought from the chief investigator and sponsor.
EthIcs And dIssEMInAtIon
The trial has received favourable opinion from the 
research ethics’ committee (15/YH/0351). Protocol 
amendments will be prepared by the core research team 
as directed by the chief investigator and TSG. Ethical 
approval will be sought. The research governance offices 
and, where applicable, the trial registry, funding body 
and dyads will be informed of the trial amendments.
research governance
The trial is sponsored by the Greater Manchester Mental 
Health NHS Foundation Trust, UK. The TSG will provide 
operational management of the trial and supervision on 
behalf of the trial sponsor and the trial funder (National 
Institute for Health Research under the Research for 
Patient Benefit programme) to ensure that the trial is 
conducted as set out in the MRC’s Guidelines for Good 
Clinical Practice. In this early phase trial, a formal data 
monitoring committee will not be convened; this function 
will be provided by the TSG. In relation to data moni-
toring, the TSG will safeguard the interests of trial dyads, 
assess the safety and efficacy of the intervention and make 
recommendations to stop the trial if warranted. The TSG 
will meet three times per year; terms of reference are 
available on request. There are no plans for interim anal-
yses at this time.
data management
Participant and companion identifiable data will be 
securely stored in locked cabinet at the University of 
Manchester. The data will be accessible by the chief inves-
tigator (IL), research coordinator (SM) and research 
assistant (SV). Coded research data (blind to which arm is 
the intervention arm) will be made available to the inde-
pendent statistician (BF) to conduct the primary analysis. 
The code will be broken only after the primary analysis 
has been completed.
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dissemination policy
Findings will be submitted to high-impact peer-reviewed 
journals, presented at national international academic 
conferences and communicated to other universities. 
Publication authorship will be based on the International 
Committee of Medical Journal Editors’ criteria. Ongoing 
dissemination to clinicians and academics will be facili-
tated through the development and regular maintenance 
of a project-specific website. A lay summary will be sent to 
dyads (if requested) and presented at community engage-
ment events.
summary
This mixed-methods protocol describes an early phase 
trial designed to primarily evaluate the feasibility and 
acceptability of CST-PD and whether there is sufficient 
evidence of clinical efficacy to justify a subsequent 
larger RCT. The protocol is congruent with the UK’s 
MRC’s updated guidance on ‘Developing and Evaluating 
Complex Interventions’10 and serves to enhance the 
design of a subsequent definitive large-scale trial.
trial status
The INVEST study and trial started on 18 January 2016 
and will be recruiting dyads from 1 March 2016 to 
30 June 2017. The end date for data collection is 
30 October 2017.
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